On 21.06.2018, Resaphene Suisse AG completed its IPO on the Vienna Stock Exchange in the Third Market segment. This step was necessary to give institutional investors the opportunity to invest. The reference price was set at 516.50 euros.
This completes the process of changing strategy in the area of financing. This was started in the summer of 2017, as Thomas Rauterkus (CFO) identified inefficient capital procurement structures and subsequently adjusted them.
Overall, the Resaphene is on the final stretch towards the professionalization of all their processes. The Board of Directors is assuming that the restructuring of medical equipment sales in the third quarter 2018 will be completed with the concentration of business units in the Lake Constance region.Back